

Newsletter



Welcome to this week's highlights!

This week, we're spotlighting research calls on global collaborations for developing vaccines to reduce Tuberculosis in sub-Saharan Africa, training hubs for Public Health fellowships, advancing vaccines for Neglected Tropical Diseases, and improving malaria therapeutics. These calls tackle key global and local health challenges.

COGNITYADVISORY

COLLABORATION FOR TUBERCULOSIS VACCINE DEVELOPMENT IN SUB-SAHARAN AFRICA

DEADLINE MODEL SINGLE-STAGE

CALL SUMMARY

This initiative supports global collaboration to develop and test TB vaccines in sub-Saharan Africa, aiming to reduce the disease burden through clinical trials and partnerships.

OPENING DATE: 30 JAN 2025

CLOSING DATE: 20 MAR 2025

CLOSING DATE: 02 SEP 2025

COGNITYADVISORY

EDCTP3 FUNDS FELLOWSHIPS IN PUBLIC HEALTH, BIOSTATISTICS, EPIDEMIOLOGY, AND MODELLING.

DEADLINE MODEL SINGLE-STAGE

CALL SUMMARY


The initiative aims to build a cohort of skilled epidemiologists, biostatisticians, and disease modellers in sub-Saharan Africa through Master's training and workshops, strengthening public health capacity and research collaboration.

OPENING DATE: 30 JAN 2025

CLOSING DATE: 20 MAR 2025

CLOSING DATE: 02 SEP 2025

COGNITYADVISORY




ACCELERATING THE DEVELOPMENT OF VACCINES FOR NEGLECTED TROPICAL DISEASES (NTDs) IN SUB-SAHARAN AFRICA.

DEADLINE MODEL
SINGLE-STAGE

OPENING DATE: 30 JAN 2025

CLOSING DATE: 20 MAR 2025

CLOSING DATE: 02 SEP 2025

 **CALL SUMMARY**

This topic aims to advance the development of prophylactic vaccines for Neglected Tropical Diseases (NTDs) in sub-Saharan Africa through clinical trials and research, focusing on safety, efficacy, and equitable access.

COGNITYADVISORY



COLLABORATION FOR RESEARCH AND CLINICAL DEVELOPMENT OF NEW AND EXISTING ANTIMALARIAL TREATMENTS.

DEADLINE MODEL
SINGLE-STAGE


OPENING DATE: 30 JAN 2025

CLOSING DATE: 20 MAR 2025

CLOSING DATE: 02 SEP 2025

 **CALL SUMMARY**

This initiative supports the development of new antimalarial drugs and combinations to combat drug resistance and reduce malaria in sub-Saharan Africa.



We discussed global collaborations for developing vaccines to reduce Tuberculosis in sub-Saharan Africa, advancing vaccines for Neglected Tropical Diseases, and improving malaria therapeutics. We also explored the importance of perseverance in research, with Winston Churchill's words in mind: "success is not final, failure is not fatal: It is the courage to continue that counts."

Discovery begins where certainty ends, and the three pillars of research guide our efforts in tackling these critical health challenges.